名称 | HT-29 (人结肠癌细胞) (STR鉴定正确) |
别称 | HT 29; HT29 |
种属 | 人 |
年龄(性别) | 女;44岁 |
组织来源 | 结直肠腺癌 |
生长特性 | 贴壁细胞 |
细胞形态 | 上皮细胞样 |
背景描述 | HT-29细胞是由J·Fogh在1964年用移植培养方法和含15%FBS的F12培养液从原发性肿瘤分离的;近来,已建株的培养细胞用含相同血清McCoy's5A培液培养。HT-29细胞在裸鼠中致瘤,也能在类固醇处理的地鼠中致瘤。HT-29细胞合成IgA、CEA、蛋白绑定TGF-β的分泌成分和粘液素等。 |
生物安全等级 | 1 |
生长培养基 | McCoy’s 5A+10% FBS+1% P/S |
推荐传代比例 | 1:3-1:4 |
推荐换液频率 | 2~3次/周 |
倍增时间 | ~36-60 hours |
冻存条件 | 冻存液:55% 基础培养基+40%FBS+5%DMSO温度:液氮 |
培养条件 | 气相:空气,95%;CO2,5%温度:37℃ |
致瘤性 | Yes, in nude mice; forms well differentiated adenocarcinoma consistent with colonic primary (grade I); tumors also form in steroid treated hamsters. |
受体表达情况 | human adrenergic alpha2A, urokinase receptor (u-PAR), vitamin D (moderate expression), urokinase receptor (u-PAR); vitamin D (moderate expression), human adrenergic alpha2A |
基因表达情况 | secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth factor beta binding protein; mucin, myc+; ras+; myb+; fos+; sis+; p53+; abl -; ros -; src -, Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5, HT-29 cells are negative for CD4, but there is cell surface expression of galactose ceramide (a possible alternative receptor for HIV). |
保藏机构 | ATCC; HTB-38 BCRJ; 0111 CCLV; CCLV-RIE 0960 DSMZ; ACC-299 ECACC; 91072201 |